Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 5;11(12):1950. doi: 10.3390/cancers11121950

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Relative risk (RR) of “diarrhea” adverse events; all grades. Combined RR for all studies was 1.19 (95% CI 0.73–1.94), showing no significant difference in risk of diarrhea between combination and monotherapy groups. There is no significant difference in encorafenib plus binimetinib in the trial by Dummer (RR: 1.08, 95% CI 0.82–1.42) or dabrafenib plus trametinib in the trial by Robert (RR: 0.85, 95% CI 0.70–1.05) when compared to vemurafenib monotherapy. Vemurafenib plus cobimetinib in the trial by Ascierto had a relative risk of 1.84 (95% CI 1.50–2.25), showing a statistically significant high risk of diarrhea when compared to vemurafenib monotherapy.